This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR \< 30 mL/min/1.73 m²).
Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.
Age between 18 and 80 years, regardless of sex.
Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines.
Complete clinical data available.
Written informed consent for participation and for undergoing 18F-FAPI PET/MR imaging is obtained from the patient or their legal guardian.
Women who are planning to conceive, currently pregnant, or breastfeeding.
Contraindications to PET/MR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties.
History of allergy or hypersensitivity to gadolinium-based contrast agents.
Presence of malignant tumors or other serious progressive diseases.